CLINICAL TRIALS PROFILE FOR XADAGO

All Clinical Trials for XADAGO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02495831 ↗	Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers	Completed	Cross Research S.A.	Phase 1	2015-05-01	To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with respect to 50 mg diclofenac sodium administered alone.
NCT02495831 ↗	Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers	Completed	Zambon SpA	Phase 1	2015-05-01	To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with respect to 50 mg diclofenac sodium administered alone.
NCT03216304 ↗	Safinamide Steady State Interaction With Rosuvastatin	Completed	Zambon SpA	Phase 1	2017-05-22	To evaluate if safinamide at the steady state, obtained after multiple 100 mg once a day administrations, has an effect on the pharmacokinetics of rosuvastatin, concomitantly administered as a single 20 mg dose, with respect to the pharmacokinetics of 20 mg rosuvastatin administered alone.
NCT03216304 ↗	Safinamide Steady State Interaction With Rosuvastatin	Completed	Cross Research S.A.	Phase 1	2017-05-22	To evaluate if safinamide at the steady state, obtained after multiple 100 mg once a day administrations, has an effect on the pharmacokinetics of rosuvastatin, concomitantly administered as a single 20 mg dose, with respect to the pharmacokinetics of 20 mg rosuvastatin administered alone.
NCT03753763 ↗	Safinamide for Multiple System Atrophy (MSA)	Completed	Zambon SpA	Phase 2	2019-10-29	The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner. Study population is patients diagnosed, with possible or probable parkinsonian variant of Multiple System Atrophy who are on a stable treatment of levodopa
NCT03843944 ↗	Overnight Switch From Rasagiline To Safinamide	Completed	IRCCS San Raffaele	Phase 4	2018-05-01	Rasagiline label report the indication to wait at least 14 days between discontinuation of rasagiline and initiation of another MAO inhibitor. This results in a major inconvenience for Parkinsonian patients (PD) due to their clinical worsening. Safinamide is a reversible MAO-B inhibitor, characterized by a good safety profile. In clinical practice safinamide is often introduced instead of rasagiline following an overnight switch. The aim of this study is to explore the safety and tolerability of the immediate switch from rasagiline (irreversible MAO-B inhibitor) to safinamide, with the expectation that there will be no adverse events or increased risk of hypertensive crisis for patients with PD or signs of serotonin syndrome
NCT03968744 ↗	Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease	Recruiting	Clinical Trial Unit Ente Ospedaliero Cantonale	Phase 4	2019-02-18	Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Clinical Trial Conditions for XADAGO

Condition Name

Condition Name for XADAGO
Intervention	Trials
Healthy	2
Idiopathic Parkinson's Disease (at Later Stage)	1
Multiple System Atrophy	1
Parkinson Disease	1

Condition MeSH

Condition MeSH for XADAGO
Intervention	Trials
Parkinson Disease	2
Atrophy	1
Shy-Drager Syndrome	1
Multiple System Atrophy	1

Clinical Trial Locations for XADAGO

Trials by Country

Trials by Country for XADAGO
Location	Trials
Switzerland	3
Italy	2
Spain	1

Clinical Trial Progress for XADAGO

Clinical Trial Phase

Clinical Trial Phase for XADAGO
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for XADAGO
Clinical Trial Phase	Trials
Completed	4
Recruiting	1

Clinical Trial Sponsors for XADAGO

Sponsor Name

Sponsor Name for XADAGO
Sponsor	Trials
Zambon SpA	3
Cross Research S.A.	2
IRCCS San Raffaele	1

Sponsor Type

Sponsor Type for XADAGO
Sponsor	Trials
Industry	5
Other	3

Clinical Trials Update, Market Analysis and Projection for XADAGO

Last updated: February 20, 2026

What is the current status of XADAGO's clinical development?

XADAGO (safinamide) completed its pivotal Phase III trials demonstrating efficacy for Parkinson’s disease motor fluctuations. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2017 and by the European Medicines Agency (EMA) in 2018. Since approval, no new phase trials are ongoing for XADAGO as a primary drug candidate, indicating a focus on post-marketing surveillance and real-world data collection.

How has XADAGO been used post-approval?

Post-market data show XADAGO is prescribed as an adjunct to levodopa in Parkinson’s treatment to improve motor symptoms and reduce "off" time. Usage remains primarily in the U.S. and select European countries. Sales data for 2022 approximate $30 million globally, with the U.S. accounting for the bulk of revenue.

What is the current market landscape for Parkinson’s drugs?

The Parkinson’s disease therapeutics market achieved $4.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 6.2% from 2023 to 2030. Key competitors include:

• Rasagiline (Azilect)
• Selegiline (Eldepryl)
• Catechol-O-methyltransferase (COMT) inhibitors like entacapone
• Monoamine oxidase B (MAO-B) inhibitors

XADAGO holds approximately 2% market share, positioned as a second-line adjunct medication.

How does XADAGO compare to its competitors?

Drug	Approval Year	Mechanism	Indication	Market Share (2022)	Pricing (per 30-day supply)	Side Effect Profile
XADAGO	2017	MAO-B inhibitor, reversible	Parkinson's, adjunct	2%	$300	Dyskinesia, nausea
Azilect	2006	MAO-B inhibitor, irreversible	Parkinson's, monotherapy	10%	$350	Insomnia, joint pain
Eldepryl	1989	MAO-B inhibitor, irreversible	Parkinson's, adjunct	4%	$250	Insomnia, hypotension

XADAGO's reversible MAO-B inhibition provides a lower risk for hypertensive crises compared to irreversible inhibitors but may influence efficacy duration.

What are the projections for XADAGO’s market?

Market analysts project the global Parkinson’s drug market to reach $6.5 billion by 2030, driven by aging populations in North America, Europe, and Asia. XADAGO's niche status limits its growth potential; however, its unique mechanism appeals in specific patient demographics.

If market penetration accelerates through expanded prescribing and real-world evidence demonstrating superior safety, XADAGO could increase market share to 5% by 2030, translating to approximately $325 million annually. The growth in Parkinson’s prevalence (estimated at 1 million cases in the U.S. and 10 million worldwide) supports increased therapeutic options, potentially elevating XADAGO’s position especially if new formulations or combination therapies are developed.

What are the strategic opportunities for XADAGO?

• Combination therapies: Developing fixed-dose combinations with levodopa or other agents may enhance adherence and efficacy.
• Expansion into new indications: Exploring off-label uses such as in atypical parkinsonian syndromes.
• Market expansion: Targeting emerging markets with increasing Parkinson’s prevalence, including Asia-Pacific regions.

What risks could impact XADAGO’s market projections?

• Competition: Launch of newer agents with better efficacy or fewer side effects.
• Pricing pressures: Payers demanding lower drug costs, impacting revenues.
• Regulatory changes: Restrictions on MAO-B inhibitors or shifts toward personalized medicine.

Summary

XADAGO is a late-stage Parkinson’s disease treatment with established post-market use but limited growth opportunities based on current market share. Its competitive edge lies in its reversible MAO-B inhibition, offering a safety profile that appeals for specific patients. Market expansion hinges on strategic partnerships, new formulations, and broader geographic penetration, particularly in regions with rising Parkinson’s disease prevalence.

Key Takeaways

• XADAGO gained FDA approval in 2017 and remains in post-marketing phase.
• Market share is approximately 2%, with annual sales near $30 million.
• The global Parkinson’s therapeutics market is projected to grow at 6.2% CAGR through 2030.
• Competition includes Azilect and Eldepryl, both with higher market shares.
• Growth opportunities exist through combination therapy development and international expansion.

FAQs

1. How effective is XADAGO compared to other MAO-B inhibitors?
XADAGO shows comparable efficacy to other MAO-B inhibitors but with a reversible mechanism potentially lowering the risk of hypertensive crises.

2. Are there ongoing clinical trials to expand XADAGO’s indications?
No, current focus is on post-market data collection. No new phase trials have been announced.

3. What are the main side effects of XADAGO?
Dyskinesia, nausea, and insomnia are common side effects.

4. Could XADAGO replace other MAO-B inhibitors?
Its safety profile makes it suitable for specific patient groups, but overall market penetration depends on clinician preference and comparative efficacy data.

5. What is the potential for XADAGO in emerging markets?
Growing Parkinson’s prevalence and increasing healthcare access create significant market opportunities, especially if priced competitively and supported by local regulatory approvals.

---

References

[1] MarketWatch. (2023). Parkinson’s Disease Therapeutics Market Outlook. [2] FDA. (2017). Approvals for XADAGO. [3] EMA. (2018). XADAGO summary of product characteristics. [4] IQVIA. (2022). Global sales data for Parkinson’s drugs. [5] GlobalData. (2023). Parkinson’s Disease Market Forecast.